Total Payments
$865,107
2024 Payments
$119,398
Companies
44
Transactions
2,485
Medicare Patients
2,605
Medicare Billing
$276,456
Payment Breakdown by Category
Other$599,412 (69.3%)
Consulting$119,520 (13.8%)
Travel$94,397 (10.9%)
Food & Beverage$38,863 (4.5%)
Research$12,027 (1.4%)
Education$889.30 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $588,417 | 262 | 68.0% |
| Consulting Fee | $119,520 | 48 | 13.8% |
| Travel and Lodging | $94,397 | 303 | 10.9% |
| Food and Beverage | $38,863 | 1,846 | 4.5% |
| Unspecified | $12,027 | 7 | 1.4% |
| Honoraria | $8,260 | 4 | 1.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,735 | 1 | 0.3% |
| Education | $889.30 | 14 | 0.1% |
Payments by Type
General
$853,080
2,478 transactions
Research
$12,027
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $239,900 | 447 | $0 (2024) |
| GENZYME CORPORATION | $207,621 | 309 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $142,065 | 203 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $67,531 | 160 | $0 (2024) |
| Celgene Corporation | $44,585 | 118 | $0 (2024) |
| Genentech USA, Inc. | $41,585 | 93 | $0 (2024) |
| TG Therapeutics, Inc. | $29,474 | 36 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $27,878 | 23 | $0 (2024) |
| UCB, Inc. | $23,371 | 213 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $18,555 | 172 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $119,398 | 390 | TG Therapeutics, Inc. ($29,340) |
| 2023 | $60,535 | 349 | Alexion Pharmaceuticals, Inc. ($28,148) |
| 2022 | $96,715 | 302 | Biogen, Inc. ($53,177) |
| 2021 | $73,507 | 277 | Biogen, Inc. ($28,588) |
| 2020 | $119,318 | 229 | Biogen, Inc. ($69,298) |
| 2019 | $149,775 | 342 | Alexion Pharmaceuticals, Inc. ($47,048) |
| 2018 | $108,203 | 277 | GENZYME CORPORATION ($49,908) |
| 2017 | $137,658 | 319 | GENZYME CORPORATION ($103,421) |
All Payment Transactions
2,485 individual payment records from CMS Open Payments — Page 1 of 100
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $3.26 | General |
| Category: PAIN | ||||||
| 12/19/2024 | UCB, Inc. | Rystiggo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: Neurology | ||||||
| 12/19/2024 | UCB, Inc. | Zilbrysq (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Neurology | ||||||
| 12/19/2024 | UCB, Inc. | Zilbrysq (Drug) | Travel and Lodging | Cash or cash equivalent | $60.97 | General |
| Category: Neurology | ||||||
| 12/19/2024 | UCB, Inc. | Rystiggo (Drug) | Travel and Lodging | Cash or cash equivalent | $40.20 | General |
| Category: Neurology | ||||||
| 12/19/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $32.64 | General |
| Category: Rare Disease | ||||||
| 12/18/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $15.72 | General |
| Category: Neurology | ||||||
| 12/18/2024 | LivaNova USA, Inc. | VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Neurology | ||||||
| 12/16/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: Immunology | ||||||
| 12/13/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $32.07 | General |
| Category: Neurology | ||||||
| 12/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $6.70 | General |
| Category: NEUROSCIENCE | ||||||
| 12/11/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $20.43 | General |
| Category: Neurology | ||||||
| 12/11/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $12.10 | General |
| Category: Central Nervous System | ||||||
| 12/09/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: Immunology | ||||||
| 12/09/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $3.28 | General |
| Category: PAIN | ||||||
| 12/06/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $23.92 | General |
| Category: Rare Disease | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.67 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $6.15 | General |
| Category: Neurology | ||||||
| 12/05/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $12.44 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: Neurology | ||||||
| 12/02/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $43.84 | General |
| Category: Neurology | ||||||
| 11/30/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Consulting Fee | Cash or cash equivalent | $565.00 | General |
| Category: Immunology | ||||||
| 11/29/2024 | UCB, Inc. | Zilbrysq (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Neurology | ||||||
| 11/27/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $10.68 | General |
| Category: PAIN | ||||||
| 11/26/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $11.40 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | Alexion Pharmaceuticals, Inc. | $12,027 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 622 | 833 | $206,872 | $71,885 |
| 2022 | 9 | 668 | 912 | $184,054 | $70,041 |
| 2021 | 8 | 710 | 953 | $194,178 | $76,594 |
| 2020 | 12 | 605 | 788 | $156,839 | $57,937 |
Total Patients
2,605
Total Services
3,486
Medicare Billing
$276,456
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 291 | 419 | $101,817 | $35,159 | 34.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 124 | 124 | $39,432 | $13,523 | 34.3% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 57 | 107 | $19,835 | $7,428 | 37.5% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 44 | 44 | $17,799 | $6,478 | 36.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 79 | 82 | $14,104 | $4,652 | 33.0% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 13 | 31 | $10,323 | $3,105 | 30.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 26 | $3,562 | $1,539 | 43.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 235 | 351 | $76,068 | $29,390 | 38.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 74 | 74 | $23,140 | $8,244 | 35.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 105 | 119 | $17,948 | $7,178 | 40.0% |
| 95911 | Nerve conduction, 9-10 studies | Facility | 2022 | 52 | 52 | $13,412 | $5,120 | 38.2% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 34 | 67 | $12,367 | $4,925 | 39.8% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2022 | 30 | 30 | $13,080 | $4,768 | 36.5% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2022 | 70 | 135 | $13,396 | $4,576 | 34.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 29 | 45 | $6,203 | $2,462 | 39.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $5,386 | $2,130 | 39.5% |
| 95909 | Nerve conduction, 5-6 studies | Facility | 2022 | 13 | 13 | $2,022 | $754.50 | 37.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 12 | 12 | $1,032 | $493.97 | 47.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 265 | 371 | $74,942 | $31,505 | 42.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 98 | 98 | $30,380 | $10,472 | 34.5% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 64 | 125 | $22,830 | $9,459 | 41.4% |
| 95911 | Nerve transmission studies, 9-10 studies | Office | 2021 | 45 | 45 | $19,751 | $7,677 | 38.9% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Facility | 2021 | 77 | 146 | $14,454 | $5,003 | 34.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 72 | 77 | $10,549 | $4,296 | 40.7% |
| 95911 | Nerve transmission studies, 9-10 studies | Facility | 2021 | 40 | 40 | $10,360 | $3,869 | 37.3% |
About Dr. James Winkley, M.D
Dr. James Winkley, M.D is a Sleep Medicine healthcare provider based in Lexington, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932120011.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Winkley, M.D has received a total of $865,107 in payments from pharmaceutical and medical device companies, with $119,398 received in 2024. These payments were reported across 2,485 transactions from 44 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($588,417).
As a Medicare-enrolled provider, Winkley has provided services to 2,605 Medicare beneficiaries, totaling 3,486 services with total Medicare billing of $276,456. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Sleep Medicine
- Other Specialties Neurology
- Location Lexington, KY
- Active Since 07/22/2006
- Last Updated 12/16/2020
- Taxonomy Code 2084S0012X
- Entity Type Individual
- NPI Number 1932120011
Products in Payments
- LEMTRADA (Drug) $122,925
- VUMERITY (Drug) $100,454
- AUBAGIO (Drug) $84,370
- TYSABRI (Biological) $67,045
- ZEPOSIA (Drug) $57,124
- TECFIDERA (Drug) $48,438
- ULTOMIRIS (Biological) $48,082
- AUSTEDO (Drug) $44,320
- SOLIRIS (Drug) $40,155
- OCREVUS (Biological) $37,848
- BRIUMVI (Drug) $29,474
- Austedo XR (Drug) $21,897
- Soliris (Drug) $14,969
- Rystiggo (Drug) $14,148
- Ozanimod (Drug) $14,097
- ULTOMIRIS (Drug) $12,027
- Tysabri (Biological) $8,671
- MAYZENT (Drug) $8,317
- UPLIZNA (Biological) $7,779
- Zilbrysq (Drug) $6,111
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Sleep Medicine Doctors in Lexington
Dr. Clarence Coker, Md, MD
Sleep Medicine — Payments: $8,467
Sleep Medicine $8,467
Stephanie Sheffield, M.d, M.D
Sleep Medicine — Payments: $2,398
Sleep Medicine $2,398
Subhendu Rath, Md, MD
Sleep Medicine — Payments: $1,117
Sleep Medicine $1,117
Dr. Jennifer Butler, Md, MD
Sleep Medicine — Payments: $937.80
Sleep Medicine $937.80